Damaraju Vijaya L, Sawyer Michael B, Mackey John R, Young James D, Cass Carol E
Department of Oncology, University of Alberta, Edmonton, Alberta, Canada.
Nucleosides Nucleotides Nucleic Acids. 2009 May;28(5):450-63. doi: 10.1080/15257770903044499.
This review describes recent advances in developing human nucleoside transporters (hNTs) as biomarkers to predict response to nucleoside analog drugs with clinical activity. Understanding processes that contribute to drug response or lack thereof will provide strategies to potentiate efficacy or avoid toxicities of nucleoside analog drugs. hNT abundance, evaluated by immunohistochemical methods, has shown promise as a predictive marker to assess clinical drug response that could be used to identify patients who would most likely benefit from nucleoside analog drug treatment.
本综述描述了在将人类核苷转运体（hNTs）开发为生物标志物以预测对具有临床活性的核苷类似物药物的反应方面的最新进展。了解导致药物反应或缺乏药物反应的过程将提供增强核苷类似物药物疗效或避免其毒性的策略。通过免疫组织化学方法评估的hNT丰度已显示出作为评估临床药物反应的预测标志物的前景，该标志物可用于识别最有可能从核苷类似物药物治疗中受益的患者。
